ARIAS: Zooming in on eye-based biomarkers for Alzheimer’s

Scientists are turning to retinas as a potential screening target for early signs of Alzheimer’s, an incurable neurodegenerative disease that affects an estimated six million people in the U.S. alone.

The Atlas of Retinal Imaging in Alzheimer’s Study (ARIAS) aims to amass a reference database of retinal changes alongside traditional and exploratory outcomes that track with disease. ARIAS is recruiting participants from hospitals in Florida and Rhode Island. Redenlab are proud to partner with the PI Prof Peter Snyder to provide digital speech and language metrics over the 5 year study. We are exploring the utility and sensitivity of meaningful speech and language testing in healthy, mild cognitive impairment and early stage dementia for use in clinical trials.

To find out more about the findings, click here.

Related Post

  • Posted on 30 May, 2024
    Join Redenlab at the upcoming Huntington’s Disease Society of America (HDSA) National Convention, starting on the 30th of May 2024...
    • Posted on 31 March, 2024
      Speech and language impairments are core features of the neurodevelopmental genetic condition Kleefstra syndrome. The speech, language and cognitive profile...
      • Posted on 25 January, 2024
        MEDIA RELEASE Melbourne, 19 January 2024 — Redenlab, a leader in innovative healthcare solutions, ispleased to announce a groundbreaking study...